Invasive fungal infections in the ICU: how to approach, how to treat. (Q38180287)

PubMed publication ID

30 August 2017

1 reference

31 October 2020

Invasive fungal infections in the ICU: how to approach, how to treat (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

hospital-acquired infection

13 May 2020

main subject

1 reference

31 October 2020

1 reference

31 October 2020

invasive fungal infections

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

author name string

Elisabeth Paramythiotou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

Frantzeska Frantzeskaki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

Apostolos Armaganidis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

George Dimopoulos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

17 January 2014

2 references

PubMed publication ID

30 August 2017

31 October 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

31 October 2020

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

page(s)

1085-1119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

Creative Commons Attribution

13 May 2020

copyright license

1 reference

31 October 2020

0 references

Is Candida really a threat in the ICU?

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

International study of the prevalence and outcomes of infection in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candidemia in the in-patient setting: treatment options and economics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology of invasive candidiasis: a persistent public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Invasive candidiasis: update on current pharmacotherapy options and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Antibiotic stewardship in Germany: a cross-sectional questionnaire survey of 355 intensive care units.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiological trends in nosocomial candidemia in intensive care

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Risk factors for albicans and non-albicans candidemia in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Current diagnostic approaches to invasive candidiasis in critical care settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Risk factors for invasive fungal disease in critically ill adult patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candida colonization and subsequent infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Invasive aspergillosis in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Disseminated aspergillosis in intensive care unit patients: an autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Clinical implications of environmental sources for Aspergillus

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Post-operative aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Post-operative Aspergillus mediastinitis in a man who was immunocompetent: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The clinical spectrum of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Utility of Aspergillus antigen detection in specimens other than serum specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Fungal molecular diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Diagnosing invasive fungal disease in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Establishment and application of real-time quantitative PCR for diagnosing invasive aspergillosis via the blood in hematological patients: targeting a specific sequence of Aspergillus 28S-ITS2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Zygomycetes in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Epidemiology and clinical manifestations of mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Invasive mold infections following combat-related injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Zygomycosis: conventional laboratory diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

The effect of sterols on amphotericin B self-aggregation in a lipid bilayer as revealed by free energy simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Management of invasive candidiasis in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Amphotericin B lipid preparations: what are the differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Treatment of candidemia in adult patients without neutropenia--an inconvenient truth

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Invasive fungal infections in the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Association of fluconazole pharmacodynamics with mortality in patients with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

21 January 2018

Antifungals in the ICU.

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Bench-to-bedside review: Candida infections in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

How to select an antifungal agent in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Why Candida sepsis should matter to ICU physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

European expert opinion on the management of invasive candidiasis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Combination antifungal therapy: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Fungal infection in acute necrotizing pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Evolving role of early antifungals in the adult intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Pulmonary aspergillosis: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Antifungal prophylaxis for invasive mycoses in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

21 January 2018

How I treat mucormycosis

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Diagnostic Performance of the (1→3)‐β‐d‐Glucan Assay for Invasive Fungal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19011085

New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis

21 January 2018

1 reference

12 December 2020

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

12 December 2020

Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance

1 reference

12 December 2020

Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.

1 reference

12 December 2020

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey

1 reference

12 December 2020

Combined detection of mannanaemia and anti-mannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species

1 reference

12 December 2020

Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?

1 reference

12 December 2020

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

1 reference

12 December 2020

Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients

1 reference

12 December 2020

Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients

1 reference

12 December 2020

Invasive aspergillosis in critically ill patients without malignancy

1 reference

12 December 2020

Polymerase chain reaction in the diagnosis of invasive aspergillosis

1 reference

12 December 2020

Is there a role for antibody testing in the diagnosis of invasive candidiasis?

1 reference

12 December 2020

Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials

1 reference

12 December 2020

Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia

1 reference

12 December 2020

Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal

1 reference

12 December 2020

Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study

1 reference

12 December 2020

Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey

1 reference

12 December 2020

Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia

1 reference

12 December 2020

Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome

1 reference

12 December 2020

Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

1 reference

12 December 2020

A single-centre 10-year experience with Candida bloodstream infections

1 reference

12 December 2020

Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease

1 reference

12 December 2020

Nosocomial fungal infections: epidemiology, infection control, and prevention

1 reference

12 December 2020

Value of (1-3)-β-d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia

1 reference

12 December 2020

Canadian clinical practice guidelines for invasive candidiasis in adults

1 reference

12 December 2020

Administration of voriconazole in patients with renal dysfunction

1 reference

12 December 2020

Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications

1 reference

12 December 2020

No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011

1 reference

12 December 2020

Comparison of peptide nucleic acid fluorescence in situ hybridization assays with culture-based matrix-assisted laser desorption/ionization-time of flight mass spectrometry for the identification of bacteria and yeasts from blood cultures and cerebr

1 reference

12 December 2020

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

1 reference

12 December 2020

Epidemiology of nosocomial fungal infections

1 reference

12 December 2020

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

1 reference

12 December 2020

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

12 December 2020

In vitro activity of voriconazole against Candida species

1 reference

12 December 2020

Organism-dependent fungicidal activities of azoles

1 reference

12 December 2020

10.3390/MOLECULES19011085

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json

13 May 2020

PubMed publication ID

24445340

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6271196&resulttype=core&format=json